{"id":2175,"date":"2020-11-16T12:13:19","date_gmt":"2020-11-16T20:13:19","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=2175"},"modified":"2020-11-17T12:16:24","modified_gmt":"2020-11-17T20:16:24","slug":"safety-and-efficacy-of-inhaled-nebulised-interferon-beta-1a-sng001-for-treatment-of-sars-cov-2-infection-a-randomised-double-blind-placebo-controlled-phase-2-trial","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/11\/16\/safety-and-efficacy-of-inhaled-nebulised-interferon-beta-1a-sng001-for-treatment-of-sars-cov-2-infection-a-randomised-double-blind-placebo-controlled-phase-2-trial\/","title":{"rendered":"Safety and Efficacy of Inhaled Nebulised Interferon Beta-1a (SNG001) for Treatment of SARS-CoV-2 Infection: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial"},"content":{"rendered":"<p>A phase 2 randomized, double-blind, placebo-controlled trial of inhaled nebulized interferon beta-1a (SNG001) for patients hospitalized with COVID-19 (n=101) found that patients who received the study drug had greater odds of improvement on the WHO ordinal scale for clinical improvement (OSCI) (OR = 2.32) on day 15 or 16 and were more likely to recover to an OSCI score of 1 (no limitation of activities) during treatment (HR = 2.19) compared to placebo. 66 (67%) patients required supplemental oxygen at enrollment (29 in the placebo group and 37 in the study drug group).<span class=\"Apple-converted-space\">\u00a0 <\/span>Headaches were the most frequently reported adverse event (15% vs. 10% in the study drug and placebo groups, respectively). Three deaths occurred in the placebo group and none in the study drug group.<\/p>\n<p><i>Monk et al. (Nov 2020). Safety and Efficacy of Inhaled Nebulised Interferon Beta-1a (SNG001) for Treatment of SARS-CoV-2 Infection: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial. The Lancet Respiratory Medicine. <\/i><a href=\"https:\/\/doi.org\/10.1016\/S2213-2600(20)30511-7\">https:\/\/doi.org\/10.1016\/S2213-2600(20)30511-7<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A phase 2 randomized, double-blind, placebo-controlled trial of inhaled nebulized interferon beta-1a (SNG001) for patients hospitalized with COVID-19 (n=101) found that patients who received the study drug had greater odds of improvement on the WHO ordinal scale for clinical improvement (OSCI) (OR = 2.32) on day 15 or 16 and were more likely to recover&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/11\/16\/safety-and-efficacy-of-inhaled-nebulised-interferon-beta-1a-sng001-for-treatment-of-sars-cov-2-infection-a-randomised-double-blind-placebo-controlled-phase-2-trial\/\">Read more<\/a><\/div>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[28],"topic":[19],"class_list":["post-2175","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-treatment","topic-testing-and-treatment"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/2175","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=2175"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/2175\/revisions"}],"predecessor-version":[{"id":2177,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/2175\/revisions\/2177"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=2175"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=2175"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=2175"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=2175"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}